Attached files
Exhibit 10.1
Cellular
Biomedicine (Wuxi) Co., Ltd. - Basic Line of Credit -
2020042800000284
Stage:
Business application investigation
|
Handler:
Qian Zheng
|
Organization
of the handler: Renmin Zhonglu Sub-branch, Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate: Floating rate
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/28/2020, 18:08:33
|
Completed
at: 4/28/2020, 18:53:05
|
[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. for the purpose
of covering the company’s operation, maintenance and R&D
expenditures. The term of the line of credit is one year and the
loan is a working capital loan with the characteristics of interest
rate of not lower than LPR +50BP, monthly settlement, fixed
interest rate, custodian payment, and the guarantee method of
credit. Please approve.
|
|
[Opinion (cont.)]
|
Stage:
Branch risk manager
|
Handler:
Li Bo
|
Organization
of the handler: Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency:
|
Amount
under application (RMB): 0.00
|
Term
(months): 0
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/28/2020, 18:53:05
|
Completed
at: 4/29/2020, 10:02:36
|
[Opinion] The following risk control measures are recommended: 1.
Pay attention to changes in the country's macro policies and pay
close attention to the price changes of major raw materials. 2.
Strengthen credit management and pay attention to the company's
management and control in production, market, capital and other
aspects. 3. Effectively strengthen post-loan management and conduct
credit risk analysis in a timely manner to ensure the safety of the
bank's credit funds.
|
|
[Opinion (cont.)]
|
Stage:
Head of the Marketing Department
|
Handler:
Ruan Haotian
|
Organization
of the handler: Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/29/2020, 10:02:36
|
Completed
at: 4/29/2020, 15:10:40
|
[Opinion] Agree
|
|
[Opinion (cont.)]
|
Stage:
Branch analysis and evaluation (beyond the branch’s
authority)
|
Handler:
Xu Daoyou
|
Organization
of the handler: Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/29/2020, 15:21:17
|
Completed
at: 4/29/2020, 17:11:58
|
[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.
|
|
[Opinion (cont.)]
|
Stage:
Branch Risk Director (beyond the branch’s
authority)
|
Handler:
Huang Yonghong
|
Organization
of the handler: Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/29/2020, 17:11:58
|
Completed
at: 4/29/2020, 17:25:30
|
[Opinion] We agree to declare this.
|
|
[Opinion (cont.)]
|
Stage:
Branch governor (beyond the branch’s authority)
|
Handler:
Zhou Bo
|
Organization
of the handler: Wuxi Branch
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/29/2020, 17:25:30
|
Completed
at: 4/29/2020, 17:40:06
|
[Opinion] Agree
|
|
[Opinion (cont.)]
|
Stage:
Pre-examination at the headquarters
|
Handler:
Dai Jun
|
Organization
of the handler: Bank of Nanjing
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
Fully authorized
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/30/2020, 8:40:31
|
Completed
at: 4/30/2020, 10:20:41
|
[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.
|
|
[Opinion (cont.)]
|
Stage:
Countersigning stage at the headquarters
|
Handler:
Zhu Hua
|
Organization
of the handler: Bank of Nanjing
|
Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.
|
Business
type: Basic line of credit
|
Authorization:
Not authorized
|
Business
currency: RMB
|
Amount
under application (RMB): 30,000,000.00
|
Term
(months): 12
|
Day(s):
0
|
Interest
rate type:
|
|
Base
annual interest rate (%): 0.0
|
Floating
interest rate:
|
Floating
value: 0.0
|
Annual
interest rate (%): 0.0
|
Handling
fee rate (‰): 0.00
|
Margin
ratio (%): 0
|
Received
at: 4/30/2020, 10:55:19
|
Completed
at: 4/30/2020, 16:06:50
|
[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.
|
|
[Opinion (cont.)]
|